» Articles » PMID: 15405984

Physiopathology and Course of Polycythemia Vera As Related to Therapy

Overview
Journal J Am Med Assoc
Specialty General Medicine
Date 1950 Mar 18
PMID 15405984
Citations 16
Authors
Affiliations
Soon will be listed here.
Citing Articles

Myeloproliferative Neoplasms: Challenging Dogma.

Spivak J J Clin Med. 2024; 13(22).

PMID: 39598101 PMC: 11595126. DOI: 10.3390/jcm13226957.


JAK2 V617F allele burden in polycythemia vera: burden of proof.

Moliterno A, Kaizer H, Reeves B Blood. 2023; 141(16):1934-1942.

PMID: 36745865 PMC: 10163319. DOI: 10.1182/blood.2022017697.


2016 WHO Clinical Molecular and Pathological Criteria for Classification and Staging of Myeloproliferative Neoplasms (MPN) Caused by MPN Driver Mutations in the JAK2, MPL and CALR Genes in the Context of New 2016 WHO Classification: Prognostic and....

Michiels J, Tevet M, Trifa A, Niculescu-Mizil E, Lupu A, Vladareanu A Maedica (Bucur). 2017; 11(1):5-25.

PMID: 28465746 PMC: 5394501.


Thrombopoietin and its receptor in normal and neoplastic hematopoiesis.

Kaushansky K Thromb J. 2016; 14(Suppl 1):40.

PMID: 27766065 PMC: 5056461. DOI: 10.1186/s12959-016-0095-z.


Physiopathology, etiologic factors, diagnosis, and course of polycythemia vera as related to therapy according to william dameshek, 1940-1950.

Michiels J, Institute And Foundation G, Education Thrombocythemia Vera Study Group F, Ewg Mpn T Turk J Haematol. 2014; 30(2):102-10.

PMID: 24385771 PMC: 3878466. DOI: 10.4274/Tjh.2013.0029.